The discovery of activating mutations and rearrangements in specific genes has revolutionized the therapeutic approaches of lung cancer over the last years. For this reason, a strict "molecular follow-up" is mandatory to evaluate patient's disease evolution. Indeed, liquid biopsy has raised as the ...
as it has several advantages such as non-invasive, real-time dynamic monitoring, and overcoming tumor heterogeneity. Liquid biopsy has shown predictive value in immunotherapy, significantly improving the precision treatment of lung cancer patients. Herein, we review the application of ...
being tumour heterogeneity and low tumour burden. Liquid biopsy in this context could also provide additional information: if T790M ratio to activating mutation in tumour may correlate with the response to osimertinib [57,60], the allele frequency ofEGFR-activating mutations and ...
as it has several advantages such as non-invasive, real-time dynamic monitoring, and overcoming tumor heterogeneity. Liquid biopsy has shown predictive value in immunotherapy, significantly improving the precision treatment of lung cancer patients. Herein, we review the application of ...
Hatim Husain, MD, discusses the current state of liquid biopsy in non–small cell lung cancer. Hatim Husain, MD, an assistant professor of medicine at Moores Cancer Center at the University of California, San Diego Hatim Husain, MD The role of liquid biopsy has grown dramatically in non—...
A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a fast...
The analysis of cancer related signals using biological fluids—a liquid biopsy—has generated great interest in the past decade. Liquid biopsies can identify a wide range of biomolecular features and have the potential to give an indication of disease status. The liquid biopsy market is expected ...
Our findings indicate that circTOLLIP can be used as a non-invasive biomarker to distinguish early-stage NSCLC from benign lung diseases and from healthy controls, suggesting the potential application of circTOLLIP for liquid biopsy in NSCLC. ...
Molecular testing for genomic variants is recommended in advanced non-small cell lung cancer (NSCLC). Standard tissue biopsy is sometimes infeasible, procedurally risky, or insufficient in tumor tissue quantity. We present the analytical validation and concordance study ofEGFRvariants using a new 17-ge...
Liquid biopsy has been widely researched for early diagnosis, prognostication and disease monitoring in lung cancer, but there is a need to investigate its clinical utility for early-stage non-small cell lung cancer (NSCLC). We performed a meta-analysis